Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Alliant Energy Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Alliant Energy Corporation trades at $76.4 (market cap $19.73B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2× Alliant Energy Corporation's market cap, and Alliant Energy Corporation pays a 2.73% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LNT | |
|---|---|---|
Market Cap | $39.89B | $19.73B |
Sector | Health | Utilities |
52-Week High | $491.22 | $78.03 |
52-Week Low | $278.09 | $61.85 |
Enterprise Value | $38.15B | $31.45B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
LNT trades at $76.40, up 0.92% today, with a bullish technical signal and mixed earnings history including a recent Q1 2026 beat. The company shows steady revenue growth to $4.36B in 2025 and a net margin of 18.58%, supported by a $13.4B investment plan and data center demand. Analysts are split with a 52% buy rating and a $75.67 consensus target, while the stock pays a $0.54 dividend.
Outlook is positive due to strategic investments and sector tailwinds, but risks include rising debt levels and interest rate sensitivity. The stock offers growth and income appeal, though investors should monitor execution on capital expenditures and competitive pressures in the utility space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
